At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CHRO Chromocell Therapeutics Corp.
Trading 12-27 14:35:18 EST
0.6310
-0.0291
-4.41%
High0.6600
Low0.6300
Vol27.86K
Open0.6310
D1 Closing0.6601
Amplitude4.54%
Mkt Cap3.80M
Tradable Cap1.00M
Total Shares6.03M
T/O17.70K
T/O Rate1.76%
Tradable Shares1.59M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.